Evidence map›Paper›PMID 36671278›Full record

ReviewAntibiotics (Basel, Switzerland)2023

Multidrug-Resistant

Wafaa H Elwakil, Soha S Rizk, Ali M El-Halawany, Mostafa E Rateb, Ahmed S Attia

Open access · goldAbstract readReview
In one paragraph

Review in Antibiotics (Basel, Switzerland), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed, 1 pooled it
2.3field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

16 citing papers in PubMed, 1 synthesis or guideline pooled it, 24 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Membrane-Focused Strategies AgainstAntibiotics (Basel, Switzerland) · 2026
    Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Phage Therapy forAntibiotics (Basel, Switzerland) · 2025
    Review
  9. Antivirulence drugs against Acinetobacter baumannii: where do they stand?World journal of microbiology & biotechnology · 2025
    Review
  10. Review
  11. Article
  12. Article
  13. Article
  14. Review
  15. Antibiotics (Basel, Switzerland) · 2023
    Article
  16. Molecular characterization of multidrug resistantFrontiers in cellular and infection microbiology · 2023
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 2 countries.

Wafaa H ElwakilMicrobiology and Immunology Postgraduate Program, Faculty of Pharmacy, Cairo University, Cairo 11562, Egypt.
Soha S RizkMicrobiology and Immunology Postgraduate Program, Faculty of Pharmacy, Cairo University, Cairo 11562, Egypt.
Ali M El-HalawanyDepartment of Pharmacognosy, Faculty of Pharmacy, Cairo University, Cairo 11562, Egypt.ORCID 0000-0002-5864-1674
Mostafa E RatebSchool of Computing, Engineering & Physical Sciences, University of the West of Scotland, Paisley PA1 2BE, UK.ORCID 0000-0003-4043-2687
Ahmed S AttiaDepartment of Microbiology and Immunology, Faculty of Pharmacy, Cairo University, Cairo 11562, Egypt.ORCID 0000-0003-0491-1007
Cairo University · EGUniversity of the West of Scotland · GB

Funding

British Council 870195203
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

A. baumanniicarbapenem resistanceEgyptnatural productsUnited Kingdom

Identifiers

PMID36671278
PMCPMC9854726
OpenAlexW4313473109

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.